Details of the Drug

General Information of Drug (ID: DMVEK07)

Drug Name

Magnesium Sulfate

Synonyms

Magnesiumsulfat; Bitter salt; Epsom salt; Hair salt; Heptahydrate Magnesium Sulfate; Kieserite [as monohydrate]; Magnesium Sulfate In Plastic Container; Magnesium Sulphate Hydrate; Magnesium bisulfate; Magnesium hydrogensulphate; Magnesium sulfate anhydrous; Magnesium sulfate dried; Magnesium sulfate hexahydrate; Magnesium sulfate solution; Magnesium sulphate; Sal Angalis; Sal De sedlitz; Sal amarum; Sal anglicum; Sal catharticum; Sal seidlitense; Salts of england; Sulfuric acid magnesium salt; Tomix OT; MgSO4; Epsom Sa (TN); Magnesium Sulfate, Heptahydrate; Magnesium sulfate in dextrose 5% in plastic container; Magnesium(II) sulfate; OT-S; Sel d'angleterre; Sulfate, Magnesium; Sulfuric acid magnesium salt (VAN); Sulfuric acid, magnesium salt; Magnesium sulfate (1:1); Magnesium(2+) ion sulfate; OT-S (drying agent); SDA 15-062-07; Sulfuric acid magnesium salt (1:1); Sulfuric acid, C10-16 alkyl ester, magnesium salt; Sulfuric acid, magnesium salt (1:1); Sulfuric acid, mono-C10-16-alkyl esters, magnesium salts; (C10-C16) Alkylalcohol sulfuric acid, magnesium salt

Indication

Disease Entry	ICD 11	Status	REF
Acute pain	MG31	Approved	[1]

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

120.37

Topological Polar Surface Area

Not Available

Rotatable Bond Count

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 43.2 hours (in newborns) [2]

Chemical Identifiers

Formula: MgO4S
IUPAC Name: magnesium;sulfate
Canonical SMILES: [O-]S(=O)(=O)[O-].[Mg+2]
InChI: InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
InChIKey: CSNNHWWHGAXBCP-UHFFFAOYSA-L

Cross-matching ID

PubChem CID: 24083
ChEBI ID: CHEBI:32599
CAS Number: 7487-88-9
DrugBank ID: DB00653
TTD ID: D02LDN

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
N-methyl-D-aspartate receptor (NMDAR)	TT9IK2Z	NOUNIPROTAC	Antagonist	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Magnesium Sulfate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sarecycline	DMLZNIQ	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Sarecycline .	Acne vulgaris [ED80]	[13]
Framycetin	DMF8DNE	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Framycetin.	Alcoholic liver disease [DB94]	[14]
Nifedipine	DMSVOZT	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Nifedipine.	Angina pectoris [BA40]	[15]
Ofloxacin	DM0VQN3	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Kanamycin	DM2DMPO	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Kanamycin.	Bacterial infection [1A00-1C4Z]	[14]
Trovafloxacin	DM6AN32	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Sparfloxacin	DMB4HCT	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Streptomycin	DME1LQN	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Streptomycin.	Bacterial infection [1A00-1C4Z]	[14]
Gemifloxacin	DMHT34O	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Norfloxacin	DMIZ6W2	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[16]
ABT-492	DMJFD2I	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[16]
Gentamicin	DMKINJO	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Gentamicin.	Bacterial infection [1A00-1C4Z]	[14]
Omadacycline	DMR2J95	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Omadacycline.	Bacterial infection [1A00-1C4Z]	[13]
Netilmicin	DMRD1QK	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Netilmicin.	Bacterial infection [1A00-1C4Z]	[14]
Levofloxacin	DMS60RB	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Tobramycin	DMUI0CH	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Tobramycin.	Bacterial infection [1A00-1C4Z]	[14]
Minocycline	DMVN5OH	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Minocycline.	Bacterial infection [1A00-1C4Z]	[13]
Lomefloxacin	DMVRH9C	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Tetracycline	DMZA017	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Tetracycline.	Bacterial infection [1A00-1C4Z]	[13]
Etidronic acid	DM1XHYJ	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Etidronic acid.	Bone paget disease [FB85]	[17]
Risedronate	DM5FLTY	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Risedronate.	Bone paget disease [FB85]	[18]
Doxercalciferol	DM6FG1P	Moderate	Increased risk of hypermagnesemia by the combination of Magnesium Sulfate and Doxercalciferol.	Chronic kidney disease [GB61]	[19]
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Atracurium.	Corneal disease [9A76-9A78]	[20]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Mivacurium.	Corneal disease [9A76-9A78]	[20]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Pancuronium.	Corneal disease [9A76-9A78]	[20]
Dolutegravir	DMCZGRE	Major	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Dolutegravir.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Raltegravir	DMYURI6	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Raltegravir.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Paricalcitol	DMYBV3G	Moderate	Increased risk of hypermagnesemia by the combination of Magnesium Sulfate and Paricalcitol.	Hyper-parathyroidism [5A51]	[19]
Levamlodipine	DM92S6N	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Levamlodipine.	Hypertension [BA00-BA04]	[15]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Magnesium Sulfate and Felodipine.	Hypertension [BA00-BA04]	[15]
Clevidipine butyrate	DMW4M97	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Clevidipine butyrate.	Hypertension [BA00-BA04]	[15]
Baloxavir marboxil	DM1UV7F	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Baloxavir marboxil.	Influenza [1E30-1E32]	[23]
Ibandronate	DM0QZBN	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Ibandronate.	Low bone mass disorder [FB83]	[24]
Dihydrotachysterol	DMFB97P	Moderate	Increased risk of hypermagnesemia by the combination of Magnesium Sulfate and Dihydrotachysterol.	Mineral deficiency [5B5K]	[19]
Gatifloxacin	DMSL679	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[16]
Penicillamine	DM40EF6	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Penicillamine.	Rheumatoid arthritis [FA20]	[25]
Deferiprone	DMS2M7O	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Deferiprone.	Thalassaemia [3A50]	[26]
Eltrombopag	DMOGFIX	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Eltrombopag.	Thrombocytopenia [3B64]	[27]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Vecuronium.	Tonus and reflex abnormality [MB47]	[20]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Rocuronium.	Tonus and reflex abnormality [MB47]	[20]
Cinoxacin	DM4EWNS	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Cinoxacin.	Urinary tract infection [GC08]	[16]
Plazomicin	DMKMBES	Major	Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Plazomicin.	Urinary tract infection [GC08]	[14]
Nalidixic acid	DMRM0JV	Moderate	Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Nalidixic acid.	Urinary tract infection [GC08]	[28]
-----------


⏷ Show the Full List of 43 DDI Information of This Drug

References

1	Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
4	Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
5	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
6	Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
7	Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
8	Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
9	The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
10	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
11	Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
12	Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35.
13	Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):.
14	Piper BJ, Alinea AA, Wroblewski JR, et al. A Quantitative and Narrative Evaluation of Goodman and Gilman's Pharmacological Basis of Therapeutics. Pharmacy (Basel). 2019;8(1):1. Published 2019 Dec 20. [PMID: 31861770]
15	Benami M, Giladi Y, Shalev E "The combination of magnesium sulphate and nifedipine - a cause of neuromuscular blockade." Br J Obstet Gynaecol 101 (1994): 262-3. [PMID: 8193107]
16	Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108]
17	Product Information. Boniva (ibandronate). Roche Laboratories, Nutley, NJ.
18	Product Information. Bonefos (clodronate). Rhone-Poulenc Rorer Canada Inc, Laval, QC.
19	Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
20	Fuchs-Buder T, Wilder-Smith OH, Borgeat A, Tassonyi E "Interaction of magnesium sulphate with vecuronium-induced neuromuscular block." Br J Anaesth 74 (1995): 405-9. [PMID: 7734259]
21	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
22	Canadian Pharmacists Association.
23	Product Information. Xofluza (baloxavir marboxil). Genentech, South San Francisco, CA.
24	Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54. [PMID: 8845456]
25	Haagsma CJ "Clinically important drug interactions with disease-modifying antirheumatic drugs." Drugs Aging 13 (1998): 281-9. [PMID: 9805209]
26	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
27	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
28	Product Information. NegGram (nalidixic acid). Sanofi Winthrop Pharmaceuticals, New York, NY.